Oramed Pharmaceuticals (NASDAQ:ORMP) Issues Quarterly Earnings Results, Beats Expectations By $1.41 EPS

Oramed Pharmaceuticals (NASDAQ:ORMP) released its quarterly earnings data on Monday. The biotechnology company reported $1.84 earnings per share for the quarter, beating analysts’ consensus estimates of $0.43 by $1.41, FiscalAI reports.

Oramed Pharmaceuticals Stock Down 2.3%

Shares of Oramed Pharmaceuticals stock traded down $0.10 on Monday, reaching $4.20. The company’s stock had a trading volume of 167,508 shares, compared to its average volume of 231,258. The company has a market capitalization of $174.72 million, a P/E ratio of 1.62 and a beta of 1.22. The stock has a 50-day moving average price of $4.12 and a 200-day moving average price of $3.81. Oramed Pharmaceuticals has a 52-week low of $1.98 and a 52-week high of $5.19.

Wall Street Analyst Weigh In

Separately, Weiss Ratings raised shares of Oramed Pharmaceuticals from a “hold (c)” rating to a “hold (c+)” rating in a research note on Thursday, June 11th. One research analyst has rated the stock with a Hold rating, According to data from MarketBeat, the stock has a consensus rating of “Hold”.

Insiders Place Their Bets

In other Oramed Pharmaceuticals news, COO Joshua Hexter sold 137,000 shares of the company’s stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $4.46, for a total transaction of $611,020.00. Following the completion of the transaction, the chief operating officer directly owned 1,023,384 shares in the company, valued at approximately $4,564,292.64. This represents a 11.81% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Avraham Gabay sold 73,360 shares of the stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $4.51, for a total transaction of $330,853.60. Following the transaction, the chief financial officer directly owned 671,785 shares in the company, valued at approximately $3,029,750.35. The trade was a 9.85% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 20.77% of the stock is currently owned by company insiders.

Institutional Trading of Oramed Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Marshall Wace LLP purchased a new position in shares of Oramed Pharmaceuticals in the fourth quarter worth about $738,000. HRT Financial LP purchased a new stake in Oramed Pharmaceuticals during the 4th quarter valued at about $131,000. Quadrature Capital Ltd purchased a new stake in Oramed Pharmaceuticals during the 4th quarter valued at about $119,000. Squarepoint Ops LLC raised its holdings in Oramed Pharmaceuticals by 95.1% in the 4th quarter. Squarepoint Ops LLC now owns 58,272 shares of the biotechnology company’s stock valued at $166,000 after acquiring an additional 28,406 shares during the last quarter. Finally, Jane Street Group LLC raised its holdings in Oramed Pharmaceuticals by 31.2% in the 4th quarter. Jane Street Group LLC now owns 78,259 shares of the biotechnology company’s stock valued at $223,000 after acquiring an additional 18,600 shares during the last quarter. Hedge funds and other institutional investors own 12.73% of the company’s stock.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of proprietary oral drug delivery systems, with an initial emphasis on diabetes management. Headquartered in Jerusalem, Israel, the company leverages its patented protein encapsulation technology, the “Oral Delivery Platform,” to transform injectable therapies into patient-friendly oral formulations. Oramed’s platform is designed to protect sensitive proteins and peptides from degradation in the gastrointestinal tract, enabling successful absorption and systemic delivery.

The company’s lead candidate, ORMD-0801, is an oral insulin capsule for patients with type 2 diabetes, currently advancing through Phase 3 clinical trials.